Analysis shows improved prognosis evaluation in cervical cancer, suggesting molecular biomarkers can predict therapeutic responses.
Key Points
Cervical cancer prognosis evaluation improved significantly with molecular biomarkers and stratification based on NCCGs.
Molecular biomarkers identified with single-cell sequencing enhanced risk score accuracy for treatment responses in cervical cancer.
Gene set enrichment analysis validated the stratification of cervical cancer patients into high-risk and low-risk groups.
Findings indicate that utilizing NCCGs provides a new approach to precision medicine in treating cervical cancer. A significant finding includes a hazard ratio of 3.24 for survival.